{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-005536","form_type":"8-K","ticker":"IMNN","cik":"0000749647","company_name":"Imunon, Inc.","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.263991+00:00","generated_at":"2026-05-27T00:39:01.972318+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Imunon appoints Dr. Douglas Faller as CMO; Phase 3 trial on track for Q1 2025","bullets":["Dr. Douglas Faller appointed Chief Medical Officer effective Feb 18, 2025, to lead clinical strategy.","Lead program IMNN-001 for advanced ovarian cancer on track to enter Phase 3 pivotal trial in Q1 2025.","Compensation: $480k salary, 40% bonus target, inducement options for 100,000 shares with 4-year vesting.","Dr. Faller brings 30+ years of oncology/immunology experience from Takeda, Skyhawk, and academic roles."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-005536","json":"https://secwatch.observer/filing/0001493152-25-005536.json","markdown":"https://secwatch.observer/filing/0001493152-25-005536.md","text":"https://secwatch.observer/filing/0001493152-25-005536.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:39:01.972318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6c520553ce","claim":"Douglas Faller was appointed as Chief Medical Officer at Imunon, Inc..","evidence_excerpt":"On February 9, 2025, the Board of Directors of Imunon, Inc. (the “Company”) appointed Dr. Douglas Faller (age 72) as Chief Medical Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/749647/000149315225005536/0001493152-25-005536-index.htm","confidence":1.0,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Medical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}